<DOC>
	<DOCNO>NCT00783705</DOCNO>
	<brief_summary>This randomized phase II trial study inositol see well work compare placebo prevent lung cancer current former smoker bronchial dysplasia . Chemoprevention use certain drug keep cancer forming . The use inositol may prevent lung cancer . It yet know whether inositol effective placebo prevent lung cancer smoker bronchial dysplasia .</brief_summary>
	<brief_title>Inositol Preventing Lung Cancer Current Former Smokers With Bronchial Dysplasia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy myo-inositol ( inositol ) 9 gram mouth twice day 6 month versus placebo revert bronchial dysplasia current/former smoker without curatively treat Stage 0/I non-small cell lung cancer . SECONDARY OBJECTIVES : I . To define mechanism ( ) action pharmacological dose myo-inositol lung cancer chemopreventive agent evaluate change : number dysplastic lesion , Ki-67 , caspase-3 , peroxisome proliferator-activated receptor ( PPAR ) gamma , cyclin D1 , cyclin E vascular endothelial growth factor ( VEGF ) immunostaining bronchial biopsy ; gene expression analysis ribonucleic acid ( RNA ) bronchial brush cell ; change inflammatory biomarkers ( C-reactive protein [ CRP ] , monocyte chemotactic protein-1 [ MCP-1 ] , myeloid progenitor inhibitory factor-1 [ MPIF-1 ] L-Selectin ) level bronchoalveolar lavage ( BAL ) plasma treatment . II . To collect additional safety adverse event profile participant enrol intervention arm . III . To establish biospecimen repository archive future correlative study . OUTLINE : Patients stratify accord smoking status ( current v former ) , prior lung cancer ( yes v ) , number dysplastic lesion baseline ( 1 v &gt; 1 ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive oral inositol daily 2 week twice daily 6 month absence unacceptable toxicity . ARM II : Patients receive oral placebo daily 2 week twice daily 6 month absence unacceptable toxicity . Patients undergo white light autofluorescence bronchoscopy bronchoalveolar lavage , bronchial brushing , biopsy well optical coherence tomography image blood sample collection baseline completion study treatment . Samples analyze tissue biomarkers ( e.g. , PPAR gamma , Ki-67 , caspase-3 , cyclin D1 , cyclin E , VEGF ) immunohistochemistry ( IHC ) ; cytokine level ( e.g. , CRP , MCP-1 , MPIF-1 , L-selectin ) ELISA ; gene expression profile RNA microarray . After completion study treatment , patient follow within 30 day .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Histologically confirm bronchial dysplasia ≥ 1 site AND meet one follow criterion : Current former smoker ≥ 30 packyear smoke history history lung cancer Stage 0 I nonsmall cell lung cancer ( NSCLC ) curatively treat surgery ( local ablation resection ) , adjuvant chemotherapy , radiotherapy ≥ 30 packyear smoke history At least 6 month since prior surgery , adjuvant chemotherapy , radiotherapy No current evidence lung cancer CT scan No noncalcified lung nodule ≥ 10 mm diameter spiral CT scan unless cancer rule PET/CT scan biopsy ECOG performance status 01 Hemoglobin normal Leukocyte count ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 1.5 time ULN ALT AST ≤ 1.5 time ULN BUN ≤ 1.5 time ULN Chloride ≤ 1.5 time ULN Total CO_2 ≤ 1.5 time ULN Sodium ≤ 1.5 time ULN Calcium ≤ 1.5 time ULN Potassium ≤ 1.5 time ULN Phosphorus ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 30mL/min Fasting blood glucose normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No cancer within past 3 year except stage 0 I NSCLC , nonmelanomatous skin cancer , localize prostate cancer , carcinoma situ cervix , superficial bladder cancer treat &gt; 6 month ago No concurrent uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Severe chronic obstructive pulmonary disease require supplemental oxygen Uncontrolled hypertension Psychiatric illness social situation would limit compliance study requirement No schizophrenia bipolar disorder No diabetes No requirement supplemental oxygen ( continuous intermittent ) SaO_2 ≥ 90 % room air No history allergic reaction attribute inositol No history allergy ingredient study agent placebo No concurrent investigational agent At least 7 day since prior anticoagulant use ( e.g. , coumadin heparin ) More 6 month since prior participation another chemoprevention clinical trial No prior pneumonectomy No prior solid organ transplantation No concurrent lithium , carbamazepine , valproate No concurrent use natural health product contain inositol</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>